We are fortunate to have such a wealth of encephalitis knowledge as part of our board of directors.
We are committed to a long-term vision of research, advocacy and awareness.
Well-documented studies that help clinicians, patients, caregivers, insurers and researchers are lacking in this medical field of study.
We are ready to make a difference in the U.S., where there are so many unmet needs.
While our steps may be incremental, we urge you to sign up so we can alert you when there are newsworthy announcements.
Dr. Karen Bloch
She has been an investigator on several Emerging Infections Program (EIP) studies sponsored by the CDC.
She has been awarded the William Schaffner Teaching award in infectious diseases in 2003, 2008, and 2011.
She has contributed to the Infectious Diseases Society of America guidelines on the management of encephalitis (2008) and co-authored the International Encephalitis Consortium recommendations on the case definition for encephalitis (2013).
Dr. Bloch graduated from medical school at the University of Virginia (MD, 1990).
She completed internship and residency at Yale-New Haven Hospital (New Haven, CT) in 1993, and infectious disease fellowship at the University of California, San Francisco (UCSF) in 1997.
She received her Master’s in Public Health (MPH) from the University of California, Berkeley in 1996.
She is board certified in Infectious Diseases.
Becky Dennis, President
Becky Dennis is the president of Encephalitis411.org and serves as a patient advocate through speaking engagements and informative patient/caregiver sessions. As a survivor, and an “Expert by Experience,” she consults with patients in their diagnosis or recovery journey to provide guidance. She is also the author of the book, “Brain Wreck.” In the past two years, Becky has played an instrumental role in developing guidelines for an encephalitis rehabilitation toolkit with infectious disease, neurology and academia across the globe. Becky has served on multiple nonprofit boards throughout her tenure, including Encephalitis Global, The Turning Point and LifePoint. She is also a guest lecturer on entrepreneurism and journalism with the University of North Texas. In her business career, Becky is a business development and marketing consultant. She’s most known for building, launching and executing programs that fuel growth in global companies. Becky’s strong business acumen was developed in professional services B2B companies where her leadership roles included chief marketing officer, senior vice president of influencer relations, and vice president of business development and marketing. Even in a volatile economy, Becky’s visionary approach has produced exceptional results for her employers, including closing more than $9 billion in total contract value during her career.
Dr. Carol Glaser
Prior to joining Kaiser Permanente, she worked at the California State Public Health Department (CDPH) for 20 years. The first part of her tenure at CDPH was as Medical Officer and then Chief of the Viral Rickettsia Disease Laboratory (VRDL). Working with the VRDL, she set up several different syndromic surveillance projects. She initiated the California Encephalitis Project (CEP) and served as the Principal Investigator for 15 years. While at CDPH VRDL, she was also involved in syndromic surveillance for severe unexplained respiratory illnesses and severe febrile rash illnesses in pediatrics (for CAV-6 enterovirus) as well as unexplained deaths. She also served as Interim Chief of the CDPH Immunization Branch and worked with many issues related to vaccine-preventable diseases including measles and pertussis outbreaks.
Most recently she was involved in the state-wide investigation of the acute flaccid paralysis syndrome in California.
She has over 50 peer-reviewed publications; most of which are related to neurologic infectious diseases, zoonotic infections or vaccine preventable diseases. She has authored several chapters on neurologic infections and zoonotic infections.
At Kaiser Permanente, she leads the newly formed Pediatric Antimicrobial Stewardship program.
Dustin Keller, Ph.D., LPC-MHSP
He is also certified as an expert from the American Academy of Experts in Traumatic Stress.
Dustin serves as the Chief Strategic Officer for Camelot in Tennessee providing leadership and strategic development. He has also served as the Council on Children’s Mental Health Director with the Tennessee Commission on Children and Youth, the Project Director for the Tennessee Lives Count Project and has been a Lead Specialized Crisis Counselor with Youth Villages.
Working in a part-time private practice, he has worked with a variety of clients from children and families, couples, and older adults. Dustin has served on various non-profit boards including Nashville Public Radio, March of Dimes and Mediation Services. He currently serves as the Conference Chair and President for the Tennessee Conference on Social Welfare. Dustin regularly conducts trainings and workshops on a variety of issues including mental health, children and youth, and suicide prevention. After witnessing the devastation of encephalitis, Dustin decided to use his background in psychology, mental health and non-profits to help promote advocacy and awareness to improve lives impacted by encephalitis.
Angela Martin, Secretary
Possessing a B.S in Health and an M.S. in Environmental Science, she has worked in both the public and private sector on a variety of environmental issues and remediation projects.
Her experience has provided opportunity for extensive work in public engagement through committee initiatives, outreach and education. She has proven management and people skills, bringing together both government and industry toward resolution of common goals.
She brings an enthusiasm for the cause of E411 being a family member of an encephalitis survivor and witnessing first-hand the many opportunities for improvement throughout the stage cycles of the illness and recovery.
Sunny Stephens, Treasurer
A 30-year career in the music business, as manager, booking agent, and publicist for Kight led Stephens to the role of patient advocate, when Kight was diagnosed in 2011 with meningitis and encephalitis.
Feeling isolated and frustrated with the lack of information out there, through internet research, Stephens connected with Johns Hopkins, and ultimately with other compassionate leaders in the field.
With experience in the mental health field, caregiving, and hospice work, Stephens has a deep passion for helping others, and her mission is to help Encephalitis411.org raise awareness about this life-altering disorder.
Dr. Allan Tunkel
He has received numerous teaching awards and honors and is passionate about physician training and mentorship. An undergraduate of Seton Hall University, Dr. Tunkel later pursued a PhD in experimental pathology followed by a medical degree at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School. He completed his residency and chief residency in Medicine at the Hospital of the Medical College of Pennsylvania followed by a fellowship in Infectious Diseases at the University of Virginia. He is widely acknowledged as an international expert in bacterial meningitis and other central nervous system infections.
Dr. Arun Venkatesan
Dr. Venkatesan specializes in immunological/inflammatory and infectious diseases that affect the nervous system.
As Director of the Johns Hopkins Encephalitis Center, he oversees clinical activities and research, and has developed a multidisciplinary program devoted to delineating pathogenesis and optimizing diagnosis and management of autoimmune and infectious conditions that affect the central nervous system.
Dr. Venkatesan received his Ph.D. in microbiology/immunology and his M.D. from the University of California, Los Angeles, followed by an internship in internal medicine at Santa Clara Valley Medical Center.
He completed his residency in neurology at The Johns Hopkins Hospital.
He has received funding from the National Institutes of Health, Howard Hughes Medical Institute, National Multiple Sclerosis Society, and Maryland Stem Cell Research Fund.